Economic Impact of Patent Expiration: When Drug Prices Drop
When a drug’s patent expires, it doesn’t just change hands-it changes price. For patients, insurers, and pharmacies, this moment marks the start of a dramatic shift in how much they pay for medicine. What was once a costly brand-name drug can suddenly become a fraction of its original price, sometimes as low as $10 a month instead of $800. This isn’t magic. It’s economics. And it happens every single day across the U.S. and around the world.
How Patent Expiration Triggers Price Collapses
Patents give drugmakers exclusive rights to sell a medication for about 20 years. During that time, they’re the only ones allowed to make it. No competition. No pressure to lower prices. That’s why a drug like Eliquis (apixaban) could cost over $850 a month before its patent expired in 2020. Once the patent ran out, generic versions flooded the market. Within months, the same drug dropped to $10 a month. That’s a 98% price drop. The key isn’t just one generic company entering. It’s the domino effect. The first generic usually cuts prices by 15-20%. The second cuts them another 30-40%. By the time five or six companies are selling the same pill, prices often fall by 80-90%. The FDA tracks this closely. In 2023, it approved 870 generic drugs-12% more than the year before. Many of those were for high-cost medications just past their patent cliff.Why Some Drugs Don’t Drop in Price-Even After Patents Expire
Not all drugs follow this pattern. Some stay expensive long after patents expire. Take Humira (adalimumab). Its original patent expired in 2016, but prices didn’t fall until 2023. Why? Because the manufacturer, AbbVie, filed over 130 secondary patents-on tiny changes like packaging, dosing schedules, or injection devices. These weren’t new drugs. They were legal tricks to keep competitors out. This tactic, called “patent thickets,” is now common. A 2025 report from I-MAK found that 78% of new patents filed for existing drugs were not for real innovations but for ways to delay generics. Even when biosimilars (generic versions of biologic drugs) finally enter the market, prices don’t always drop right away. Why? Rebates. Insurance companies and pharmacy benefit managers (PBMs) often get big discounts from the brand-name maker in exchange for keeping it on their preferred list. So even if a cheaper biosimilar is available, your insurance might not cover it. Patients end up paying full price for the original drug-because the system rewards secrecy, not savings.Country-by-Country Price Drops
The U.S. isn’t the only place where patent expiration matters. But it’s the most extreme. A 2023 study in JAMA Health Forum looked at eight wealthy countries. After eight years, drug prices fell:- 82% in the United States
- 60% in the UK
- 58% in Germany
- 53% in France
- 48% in Canada
- 42% in Japan
- 64% in Australia
- 18% in Switzerland
What Happens When Generics Finally Arrive
The FDA’s Generic Drug User Fee Amendments (GDUFA), started in 2012, were supposed to speed up approval. And they did-for simple pills. For a basic tablet, approval now takes about 10 months. But for complex drugs-like injectables, inhalers, or biologics-it can take over two years. Why? Because testing them is expensive. A single bioequivalence study can cost $2-5 million. Only big companies can afford that. That’s why some drugs stay expensive for years after patent expiration. Take semaglutide (Ozempic, Wegovy). The base patent expires in 2026. But the manufacturer has filed 142 patents on formulations, delivery methods, and dosing schedules. Experts predict these patents could delay true generic competition until 2036. That means millions of people with diabetes or obesity may keep paying $1,000+ a month for another decade.The Real Impact on Patients and Providers
For patients, the difference is life-changing. A 2023 Kaiser Family Foundation survey found 68% of insured adults saw lower out-of-pocket costs when generics launched. But 22% said their insurance didn’t switch to the cheaper version for months-or ever. Some pharmacists report patients showing up confused: “I got the same pill, but it’s still $700. Why?” Doctors see it too. Dr. Sarah Kim, a rheumatologist in Chicago, says patients with arthritis used to skip doses because they couldn’t afford Humira. Now, with biosimilars available, many are finally getting consistent treatment. But she still sees patients stuck on expensive brands because their insurer won’t cover the cheaper option.
What’s Changing-and What’s Not
There’s momentum for reform. The Inflation Reduction Act of 2023 lets Medicare negotiate prices for 10 high-cost drugs a year. That’s forcing manufacturers to rethink their strategies. Some are rushing to launch generics before their drugs get picked for negotiation. Others are filing even more patents to stretch out exclusivity. The European Union is moving faster. Its 2024 Pharmaceutical Package limits how long companies can extend patents with minor changes. The European Medicines Agency wants 70% of patients on biosimilars within three years of patent expiry-up from 45% today. In the U.S., the Patent Trial and Appeal Board started cracking down on patent thickets in 2023. But progress is slow. Until there’s real transparency in rebate deals and faster approval for complex generics, many patients will keep paying far more than they should.What You Can Do
If you’re on a drug that just lost its patent:- Ask your pharmacist: “Is there a generic version?”
- Ask your doctor: “Can we switch to a biosimilar or generic?”
- Call your insurer: “Why isn’t the cheaper version covered?”
- Check GoodRx or NeedyMeds: They often list prices for generics before insurers update their lists.
Do all drugs drop in price after patent expiration?
Not always. Simple pills usually drop 80-90% within a few years. But complex drugs-like injectables, inhalers, and biologics-can stay expensive for years due to high approval costs, patent thickets, and insurance rebate deals. Drugs like Humira and Ozempic are examples where prices didn’t fall immediately after patent expiry.
How long does it take for generics to appear after a patent expires?
In the U.S., generics typically enter 12-30 months after patent expiry, depending on legal challenges. In Europe, it’s often 12-18 months. For complex drugs, approval can take over two years. Some companies delay entry through lawsuits or patent extensions.
Why are some generic drugs still expensive?
Even if a generic is available, your insurance may not cover it. Manufacturers often pay rebates to keep their brand on preferred lists. Also, some generics are made by only one company, so there’s no competition to drive prices down. Supply chain issues and manufacturing delays can also limit availability.
What’s the difference between a generic and a biosimilar?
Generics are exact copies of small-molecule drugs (like pills). Biosimilars are similar-but not identical-to complex biologic drugs (like injectables made from living cells). Because biologics are harder to copy, biosimilars require more testing. They’re cheaper than the original, but not always as cheap as a typical generic.
Can I ask my doctor to switch me to a generic?
Yes. In fact, you should. Ask if a generic or biosimilar is available and if it’s covered by your insurance. Most states allow pharmacists to substitute generics unless your doctor writes “dispense as written.” But you need to initiate the conversation-many providers assume patients know about generics.
You might like
